News
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded ...
4d
GlobalData on MSNExact Sciences expands partnership with Humana to improve colorectal cancer screeningThe Cologuard Plus test is being offered as an in-network service to eligible Humana Medicare Advantage members.
Louisville, Ky.-based Humana contracted with Madison, Wis.-based Exact Sciences Corp. to cover Cologuard — a colon cancer test — as an in-network service for its members.
Here are four updates on gastroenterology and endoscopy companies. London-based Lumendi received 510(k) clearance from the FDA for its DiLumen, an endoscopic accessory. Laval, Quebec-based Valeant ...
Fact checked by Nick Blackmer Cologuard is getting an upgrade soon. An updated at-home screening test, called Cologuard Plus, is expected to be available in June 2025. Cologuard Plus is a more ...
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration approved the Cologuard Plus™ test, the company’ s next ...
Cologuard Plus: 93.9% (95% CI, 87.1-97.7) sensitivity for colorectal cancer; 43.4% (95% CI, 41.3-45.6) sensitivity for advanced precancerous lesions; ...
In average-risk adults, Cologuard Plus demonstrated sensitivities of 95% for CRC and 43% for advanced precancerous lesions at 94% specificity in the pivotal BLUE-C trial.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results